HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $20.6M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
219% more capital invested
Capital invested by funds: $6.47M → $20.6M (+$14.2M)
62% more funds holding
Funds holding: 13 → 21 (+8)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$133K |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$88.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.3K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$57.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$52.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$126K |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$53.4K |
| 3 |
IF
Ironwood Financial
Tucson,
Arizona
|
-$3.37K |
HTGM Hedge Fund Activity: Q1 2017 in Review
21 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2017, worth a combined $20.6M — up 219% from $6.47M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HTGM positions and 0 closed out — a net gain of 9 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was State Street, opening a new position worth an estimated $133K. The largest seller was Renaissance Technologies, cutting an estimated $126K.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2017, up from 13 in Q4 2016.
- Funds reported $20.6M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2017, up 219% quarter-over-quarter.
- 9 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2017 and 0 closed out, a net change of +9 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2017 was State Street, an estimated $133K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2017 was Renaissance Technologies, an estimated $126K sold.
Based on aggregated 13F filings for Q1 2017.